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Abstract: Bisphosphonates (BPs) are widely used in the treatment of postmenopausal 
  osteoporosis and other metabolic bone diseases. They bind strongly to bone matrix and reduce 
bone loss through inhibition of osteoclast activity. They are classified as nitrogen- and non-
nitrogen-containing bisphosphonates (NBPs and NNBPs, respectively). The former inhibit 
farnesyl diphosphate synthase while the latter induce the production of toxic analogs of adenosine 
triphosphate. These mechanisms of action are associated with different antifracture efficacy, 
and NBPs show the most powerful action. Moreover, recent evidence indicates that NBPs can 
also stimulate osteoblast activity and differentiation. Several randomized control trials have 
demonstrated that NBPs significantly improve bone mineral density, suppress bone turnover, 
and reduce the incidence of both vertebral and nonvertebral fragility fractures. Although they 
are generally considered safe, some side effects are reported (esophagitis, acute phase reaction, 
hypocalcemia, uveitis), and compliance with therapy is often inadequate. In particular, gastro-
intestinal discomfort is frequent with the older daily oral administrations and is responsible for 
a high proportion of discontinuation. The most recent weekly and monthly formulations, and in 
particular the yearly infusion of zoledronate, significantly improve persistence with treatment, 
and optimize clinical, densitometric, and antifracture outcomes.
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Introduction
Bisphosphonates (BPs), synthetic analogs of the endogenous bone mineralization 
regulator pyrophosphate, are the most commonly used drugs in the treatment of post-
menopausal osteoporosis (PO) and metabolic bone disease (MBD, such as bone loss 
induced by hormone suppressive therapy or glucocorticoids). BPs have been associated 
with significant improvement in bone mineral density (BMD), suppression of bone 
turnover, and reduction of fracture incidence. Fractures are the most important cause 
of morbidity and mortality among patients with MBD, and reduction of fracture risk 
is the main goal of treatment.1–4
BPs have been known for more than a century, and were initially used in toothpaste 
or to soften hard water. Nowadays, they are widely used in the treatment of skeletal 
diseases and are usually classified into two classes, ie, nitrogen- and non-nitrogen-
containing bisphosphonates (NBPs and NNBPs, respectively).
All bisphosphonates reduce osteoclast activity, but NBPs (alendronate, risedronate, 
ibandronate, zoledronate) specifically inhibit farnesyl diphosphate synthase and block 
prenylation of guanosine triphosphate-binding protein, although other mechanisms 
of action have been recently identified.5 In contrast, NNBPs (etidronate, clodronate), Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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the older molecules, induce the production of toxic analogs 
of adenosine triphosphate. The antifracture effect is also 
dependent on the different affinity of each type of molecule 
for the bone mineral matrix and in this respect the NBPs 
show the most powerful action.
There are various BP formulations and dosages. NBPs 
were initially administered orally once daily (alendronate 
10 mg and risedronate 5 mg), then weekly (risedronate 
35 mg and alendronate 70 mg), monthly (risedronate and 
ibandronate 150 mg), and, more recently, intravenous for-
mulations have been developed (ibandronate 3 mg every 
3 months and zoledronate 5 mg yearly). Adherence to treat-
ment was quite difficult with daily dosages, mainly due to 
gastrointestinal (GI) intolerance,6 which is clinical important 
because poor compliance compromises treatment efficacy, 
and increases fracture incidence and medical costs.7
Compliance has been significantly increased with more 
recent weekly and monthly formulations,6 and particularly 
with intravenous yearly administration, which also improves 
clinical, densitometric, and antifracture outcomes.8,9
This review summarizes the pharmacologic properties, 
efficacy, tolerability, and safety of the most common and 
effective NBPs in the treatment of PO and MBD.
Pharmacokinetic  
and pharmacodynamic profiles
BPs are analogs of inorganic pyrophosphate, and composed of 
an enzyme-resistant phosphorus-carbon-phosphorus (P-C-P) 
structure able to adhere strongly to hydroxyapatite crystals 
(Figure 1). They have a relatively simple core structure, and 
the pharmacologic properties of each BP molecule depend 
on lateral chains, named R1 and R2.8 The P-C-P nucleus and 
R1 lateral chain are responsible for anchoring the drug to the 
bone mineral matrix, while R2 has biologic and therapeutic 
actions. The presence of a hydroxyl group in R1 markedly 
increases BP affinity for the bone matrix, while the nitrogen 
atom in R2 is responsible for antiresorptive potency.5
BPs are characterized by low GI absorption after oral 
administration, high affinity for bone matrix, urinary elimina-
tion, and long persistence on the bone surface.10 To increase 
intestinal absorption, BPs must be taken on an empty stomach, 
with water, at least 30–45 minutes before eating. This problem 
is obviously avoided using intravenous formulations.
Plasma half-life is very short, and BPs are cleared from 
plasma in about six hours; 50% of the absorbed drug 
adheres to the bone surface, while the remainder is excreted 
unchanged in urine.11 BPs persist in bone for a long 
time. For example, the effect of alendronate in humans is 
  maintained for many years after discontinuation of prolonged 
treatment.1,12,13 The time that a BP resides within the skeleton, 
which is   important for its biologic actions, is determined by 
three critical   factors; firstly, the rate of bone remodeling in the 
host (faster remodeling means a shorter half-life), secondly, 
the side chain that, as mentioned above, greatly influences 
BP affinity for bone matrix, and, finally, the amount of drug 
reaching bone. For example, intravenous administration 
increases the speed and amount of drug reaching the bone 
and also the urinary system where the drug is eliminated; on 
the other hand, oral   administrations have the problem of low 
intestinal   absorption, with only a small portion of each single 
dose administered being able to reach the bone matrix.
BPs bind to plasma proteins and are eliminated by the 
kidney.11 They are not metabolized by the liver, and no other 
metabolites have been found in serum. Drug interactions are 
very few and they relate mainly to impaired oral absorption 
if they are administered concomitantly with other drugs or 
food.14 Some cases of hypocalcemia have been observed 
during treatment with aminoglycoside antibiotics.15
Due to their strong affinity for the skeleton, BPs are 
used in many skeletal diseases in addition to OP, including 
Paget’s disease of bone, osteogenesis imperfecta, malignant 
hypercalcemia, metastatic cancer, and fibrous dysplasia. 
Dose and frequency of BP administration depend on the 
characteristics of each compound and on the type of disease 
being treated.
The therapeutic effect of BPs is mediated mainly by the 
inhibition of osteoclastic bone resorption, as demonstrated in 
bone biopsies, where fewer numbers of osteoclasts and lower 
bone erosion rates have been observed.12 Once embedded on 
the bone surface, BPs are slowly released into the bone matrix 
where they affect osteoclasts by reducing their differentiation, 
recruitment, and activity. In fact, it is believed that BPs are 
taken up by osteoclasts during bone resorption and, under 
their influence, osteoclasts lose their ruffled border and their 
normal cytoskeleton structure.12,17
NBPs (eg, alendronate, risedronate, ibandronate, zole-
dronate) interfere with protein prenylation by inhibiting 
farnesyl pyrophosphate (FPP) synthase, thereby reducing 
geranylgeranyl diphosphate metabolites involved in the 
mevalonate pathway. Inhibition of this pathway prevents 
posttranslational prenylation of small guanosine triphos-
phate-binding proteins (eg, Ras, Rho, and Rac), which 
regulate osteoclast morphology, cytoskeletal arrangement, 
membrane ruffling and trafficking, and lead to reduced 
resorptive activity and accelerated apoptosis (programmed 
cell death).18,19 Some authors have suggested that osteoclast Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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inhibition by NBPs could also be osteoblast-mediated via the 
production of an inhibitory factor not yet characterized.20
Moreover, increasing evidence indicates that osteoblast activ-
ity could be directly stimulated by NBPs. Histomorphometric 
analysis in osteoporotic patients indicates that BPs may increase 
the mean wall thickness and reduce the imbalance between for-
mation and resorption at the basic multicellular unit,16,21 leading 
to a continuing increase in BMD even after a long period of 
treatment, as demonstrated in clinical studies.1,16
NBPs also control osteoblastic proliferation and differ-
entiation,22 modulate osteoblast production of   extracellular 
matrix proteins, regulate the secretion of several cytokines 
and growth factors, and enhance proliferation and maturation 
of bone marrow stromal cells into the osteoblastic lineage.23 
In addition, NBPs are able to prevent glucocorticoid-induced 
apoptosis of osteoblasts and osteocytes.24 The mechanism 
by which BPs stimulate osteoblasts is not completely 
understood. A type of anabolic effect has been associated 
with the stimulation of b-FGF.25 The involvement of bone 
morphogenetic protein 226 has been postulated, including 
a cascade of osteoblast-related genes like RUNX2, Type 1 
collagen, and bone sialoproteins. The OPG/RANKL system 
has been shown to be upregulated and significantly increased 
in bone marrow stromal cells after NBP treatment.23,27 We 
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have also recently observed (Dalle Carbonare, unpublished 
data) an upregulation of Cox-2 expression in osteoblasts after 
NBP treatment, indicating a possible role of exogenous and 
endogenous prostaglandins, known to be involved in bone 
formation and remodelling.28
Mechanism of action  
of zoledronic acid
Zoledronic acid is an NBP and, like the other molecules of 
this class, binds to hydroxyapatite in the bone mineral matrix 
and strongly inhibits bone resorption. The ability of BPs 
to persist in bone matrix and to reduce osteoclast activity 
depends on their affinity for the bone matrix and potency 
of the inhibition of FPP.18 Zoledronic acid has the highest 
affinity for bone, followed by alendronate, ibandronate, 
risedronate, etidronate, and clodronate and it also alters 
mineral-surface properties, allowing greater adsorption. 
These properties are believed to contribute to its prolonged 
action.29
The potency of zoledronic acid appears to be related 
also to its unique chemical structure. All BPs have a P-C-P 
nucleus that acts as a bone hook, while R2 is the structure 
primarily responsible for antiresorptive potency and dura-
tion of action. R2 in zoledronic acid is composed of a het-
erocyclic ring containing two nitrogen atoms (Figure 1).29,30 
Biochemical assays have demonstrated the antiresorptive 
potency of this bisphosphonate. In in vitro analysis of FPP 
synthase inhibition, zoledronic acid was the most potent BP 
evaluated, followed by risedronate, ibandronate, alendronate, 
and pamidronate31 (Figure 2). The ability to inhibit FPP is 
directly correlated with effectiveness in suppressing bone 
turnover in vivo.
As already mentioned, the bioavailability of the BPs is 
very low when they are administered orally, but this problem 
is avoided by intravenous administration, such as with the 
yearly formulation of zoledronic acid. Orally administered 
BPs have shown approximately 1% bioavailability, whereas 
intravenous formulations have shown 100% bioavailability.
Like the other BPs, zoledronic acid is eliminated rap-
idly in the urine, and studies of its endogenous metabolism 
have shown that it does not inhibit human cytochrome 
activity in vitro, in particular the p450 enzyme, or undergo 
biotransformation in vivo, indicating that it is not extensively 
metabolized.32–34
Bone turnover markers
Serum and urinary markers of bone metabolism are important 
biochemical tests in daily clinical practice for evaluation of 
PO and MBD. The most common bone resorption markers are 
serum C-terminal collagen telopeptide, urinary N-terminal 
collagen telopeptide, and deoxypyridinoline, and for bone 
formation are alkaline phosphatase (ALP) and its bone 
isoenzyme (B-ALP) and osteocalcin.35 Patients with high 
bone turnover may have a higher risk of fracture than those 
with low bone turnover, independently of BMD.36
These bone markers are characterized by high biologic 
variability, and newer markers, such as serum RANKL, as 
well as genetic abnormalities of osteoblastic differentiation 
from mesenchymal precursors, are now under evaluation but, 
even if these are apparently more reliable, they are not still 
accessible in routine clinical practice.37,38
Bisphosphonates are potent inhibitors of bone turnover 
and significantly decrease both resorption and formation 
markers.12,13 Bone markers could be used to assess treatment 
compliance, efficacy, and disease activity.35,39
Inhibition of bone turnover in PO is similar for all the oral 
formulations of bisphosphonates (50%–70%), with a nadir 
after 6–12 months of treatment, and thereafter   returning 
back to the premenopausal range.40–42 Inhibition of bone 
turnover is maintained for the duration of treatment and 
tends to persist even after discontinuation in terms of drug 
accumulation on the bone surface and slow release   during 
osteoclastic activity.1,12,13,43 Of all the NBPs, risedronate 
seems to show the most rapid return to pretreatment levels 
(6–12 months).44
After a single intravenous dose of zoledronate, bone 
turnover marker reduction reaches up to 80% after 1 month 
and persists over the following 12 months.9,45,46 This is 
due to the high potency and affinity of zoledronic acid for 
hydroxyapatite and the 100% bioavailability afforded by the 
intravenous infusion.29,30
Excessive inhibition of bone turnover has been   suggested 
to occur with prolonged treatment and has been considered 
potentially responsible for so-called “adynamic” bone dis-
ease.47 Until now, there has not been any convincing evidence 
of such a problem, and the long-term efficacy and safety of 
NBPs are maintained, as demonstrated by the data collected 
for 10 years of alendronate and 7 years for risedronate.1,43,48
Safety and tolerability
Bisphosphonates are widely used in PO and MBD, and 
are usually well tolerated. Common side effects have been 
described, including GI intolerance, in particular esophagitis, 
as well as acute phase reaction and uveitis. These side effects 
are similar for all the molecules   available, but some of them 
are correlated with their route of administration.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Oral administration comes with specific instructions to 
optimize the adsorption and to avoid possible esophageal 
lesions. The dose must be taken on an empty stomach, with 
abundant water intake at least 30–45 minutes before eating, 
and while sitting or standing up. It has been estimated that at 
least 50% of patients taking oral BPs discontinue the therapy 
within 1 year,26 and many patients do not take their drugs 
according to the instructions described above.49–52
Post-marketing studies indicate that 20%–30% of patients 
treated with alendronate or risedronate discontinue the drug, 
mainly because of side effects.49,50 This is clinically relevant 
because poor compliance compromises treatment efficacy, 
and increases fracture incidence and medical costs.7,49
Upper gastrointestinal intolerance
GI intolerance, in particular in the upper GI tract (nausea, 
vomiting, epigastric pain, and dyspepsia), is often associated 
with the use of oral BPs.53 Esophagitis is the most important 
and frequent side effect, and its incidence was more or less 
similar in a head-to-head comparison between alendronate 
and risedronate.54 Endoscopic examination showed that 
esophagitis was caused by direct contact between the tablet 
and the mucosa. Prolonged contact of the tablet with the 
esophageal mucosa can induce local irritation; this problem 
can be prevented by strict adherence to the above-mentioned 
dosing instructions.
Esophagitis was common with daily formulations but the 
incidence has decreased significantly after the introduction of 
weekly and monthly BP administration.55 Intravenous formu-
lations of zoledronate and ibandronate avoid this problem.
Acute phase reaction
Acute phase reaction encompasses a variety of symptoms 
generally described as fever, myalgia, fatigue, chills, and 
arthralgia. It is common with all NBPs, whether adminis-
tered orally or intravenously, but is certainly more frequent 
and intense with the more potent intravenous formulations.12 
Symptoms are typically transitory, resolving within 3 days 
of onset and reduced by commonly used anti-inflammatory 
and antipyretic agents.8
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Figure 2 Farnesyl pyrophosphate synthase enzyme inhibition potency (iC50) of nitrogen-containing bisphosphonates (inhibition of 50% of maximum enzyme activity). Note 
that zoledronic acid shows the higher affinity for the mineral matrix combined with the higher inhibition potency of farnesyl pyrophosphate synthase.26
Abbreviations: ALN, alendronate; iBN, ibandronate; RiS, risendronate; ZOL, zolendronic acid.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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The symptoms are particularly common with zoledronic 
acid, and include pyrexia (16.1%), myalgia (9.5%), flu-like 
symptoms (7.8%), headache (7.1%), and arthralgia (6.3%). 
All these events decreased dramatically with subsequent 
infusions. Symptoms were reported in 30% of patients after 
the first infusion, in 6.6% after the second, and 2.8% after the 
third.8 The mechanism responsible for these effects is linked 
both to the direct stimulation of γ/δ lymphocytes and to the 
intracellular accumulation of isopentenyl pyrophosphate due 
to the inhibition of farnesyl diphosphate synthase.56
Although it is usually reported as a side effect, the stimula-
tion of a subgroup of γ/δ T-lymphocytes could be responsible 
for the indirect antineoplastic activity of zoledronic acid.57
An interesting association between acute phase reaction 
and vitamin D deficiency has recently been demonstrated, 
indicating that adequate supplementation with vitamin D 
before the infusion contributes to reduce the incidence of 
symptoms.58
Renal safety
BPs are excreted by the urinary system and can induce 
  impairment of renal function. The mechanism of the   damage 
is the same as that responsible for the therapeutic effect, 
ie, blockage of the mevalonate pathway, with apoptosis of 
tubular cells.59 Because renal damage is closely correlated 
with the concentration/time ratio of drugs in the kidney, 
intravenous formulations potentially carry a higher risk of 
renal impairment.
The renal safety of zoledronic acid has been monitored in 
the Pivotal Fracture Trial (PFT). No signs of significant renal 
dysfunction were reported following 3 years of intravenous 
treatment with zoledronic acid in patients with a baseline crea-
tinine clearance $30 mL/min. In 31 patients treated with zole-
dronic acid, a transient elevation of creatinine levels has been 
observed, which normalized completely within one month 
in 27 patients and in all patients by one year. Assessments 
at 12, 24, and 36 months showed no significant differences 
between groups in serum creatinine or creatinine clearance 
change from baseline.8,60 Moreover, the reduction of creatinine 
clearance in patients with mild to moderate renal dysfunction 
was not different from that in the placebo group.
The safety of zoledronic acid has been also tested in MBD 
where the dosage and rate of infusion are much higher than for 
PO. These patients are usually at high risk of renal   dysfunction 
from pre-existing renal disease, concomitant treatments, 
frequent use of non-steroidal anti-inflammatory drugs, and 
hypercalcemia, but data from a meta-analysis indicate that 
zoledronic acid infusion is generally safe.61   Nevertheless, 
the duration of infusion is important because a period shorter 
than 15 minutes, achieving high drug   concentrations in the 
renal tubule, could damage tubular cells. This problem can be 
avoided with an infusion exceeding 15 minutes.62 Moreover, 
because clinical studies indicate that there is no evidence of 
excessive drug accumulation secondary to renal failure, no 
adjustment of the dosage is necessary in patients with PO 
and nephropathy.62
At present, the summary of product characteristics rec-
ommends caution when using zoledronic acid in patients 
with a creatinine clearance ,30 mL/min, not because of 
established risk of toxicity, but on the basis of the limited 
data available.63
Cardiovascular safety
Atrial fibrillation (AF) is the only relevant cardiac side effect 
reported in patients treated with BPs. AF occurred in the PFT 
in 50 patients (1.3%) treated with zoledronic acid and in 
20 patients (0.6%) treated with placebo (P , 0.001).8 Nota-
bly, 47 of 50 cases of AF were recorded more than 30 days 
after zoledronic acid infusion, when the drug was no longer 
detectable in serum. Furthermore, an electrocardiogram 
substudy, conducted in 559 patients before study initiation 
and 9 to 11 days after the third infusion, failed to reveal any 
cardiac arrhythmias of note. Other cardiovascular adverse 
events, eg, stroke and myocardial infarction, did not show 
any significant difference between groups, nor was there a 
significant difference in the overall incidence of death from 
cardiovascular causes. A retrospective analysis of the Frac-
ture Intervention Trial (FIT) highlighted a trend toward a 
higher incidence of AF in patients treated with alendronate, 
similar to that observed with zoledronic acid. In this study, 
47 patients (1.5%) treated with alendronate and 31 (1%) of 
those in the placebo group developed AF.64
No studies are available to suggest a biologic mechanism 
for a relationship between BPs and development of AF. 
Alterations of serum calcium, changes in intracellular ion con-
centrations, QT prolongation, and/or production of specific 
proinflammatory, profibrotic, and antiangiogenic cytokines 
have been suggested, but no significant treatment-related 
changes in these parameters have been observed thus far.65–67 
At present, this problem seems not to be clinically relevant, 
but more extensive and specific studies should be carried out 
to clarify the relationship between AF and BP treatment.
Hypocalcemia
BPs are potent inhibitors of osteoclast activity and could 
  trigger an acute decrease of serum calcium and phosphorus Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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concentrations associated with a secondary parathyroid 
  hormone (PTH) increase.68 PTH maintains the serum calcium 
level by increasing renal tubular reabsorption and synthesis of 
1,25-dihydroxyvitamin D, and indirectly stimulates osteoclasts 
via osteoblasts. Symptomatic hypocalcemia is uncommon 
with oral bisphosphonates,69 but the more potent intravenous 
formulations may cause symptomatic hypocalcemia within 
a few days postinfusion, overcoming the PTH effect.70 Risk 
factors for hypocalcemia include the presence of hypopara-
thyroidism, vitamin D deficiency, and renal failure.
In the Health Outcomes and Reduced Incidence with 
Zoledronic Acid Once Yearly (HORIZON)-PFT study, 2.3% 
of patients in the zoledronic acid group showed hypocal-
cemia, defined as serum calcium levels ,2.075 mmol/L, 
9–11 days after the first infusion. All cases were transient 
and asymptomatic.8 In clinical practice, appropriate calcium 
and vitamin D supplementation prevents hypocalcemia, and 
correction of vitamin D deficiency is also recommended.71
Ocular adverse events
Nonspecific conjunctivitis is the most common ocular side 
effect of the BPs.72,73 This is usually transient and improves 
without specific therapy or discontinuation of BP therapy. 
Other ocular side effects, such as eye lid edema, optic or 
retrobulbar neuritis, periorbital edema, cranial nerve palsy, 
and ptosis have been reported. The most frequent cranial 
nerve side effect is optic nerve neuritis, but the release 
of cytokines after bisphosphonates administration might 
provoke also extraocular muscle inflammation and involve 
orbital motility.74
Uveitis and scleritis are the most serious ocular com-
plications of BP therapy, and require discontinuation of 
treatment. However, the true incidence of these side effects 
is unknown.72,73
A large cohort study determined the six-month incidence 
of uveitis/scleritis during BP treatment. The relative risk of 
uveitis/scleritis over 6 months was 1.23 (95% confidence inter-
val [CI] 0.85–1.79) compared with patients not treated with 
BPs. There was no significant difference in the incidence of 
uveitis/scleritis between BP users and nonusers, nor between 
oral or intravenous bisphosphonate administration.73
An association with concomitant systemic diseases (such 
as ankylosing spondylitis, Behçet syndrome, psoriasis, Reiter 
syndrome, inflammatory bowel diseases, polychondritis, 
Wegener’s granulomatosis, rheumatoid arthritis, systemic 
lupus erythymatosus, sarcoidosis, and syphilis) or treatments 
(rifabutin, trimethoprim-sulfamethoxazole, diethylcarbamaz-
ine, metipranolol, and cidofovir) have been reported, and it 
has been postulated that in these situations BPs could act as a 
precipitating factor.73 Vigilance is therefore necessary when 
BPs need to be administered in patients with these diseases 
or receiving these concomitant therapies.
Atypical femoral diaphysis fractures
In the last few years, a new association between long-term 
BP treatment and unusual, low-energy, nonvertebral fractures 
has been reported.75 Until now, this complication was reported 
only in patients taking oral BPs, in particular alendronate.76
Bone biopsies in these patients show evidence of severely 
suppressed bone turnover, considered to be the cause of 
adynamic bone disease, which presumably accounts for 
increased bone fragility resulting in atypical fractures.75 
The radiographic pattern is distinctive, and defined as a 
simple transverse or oblique (#30°) fracture, with breaking 
of the cortex and diffuse cortical thickening of the proximal 
femoral shaft.77
The majority of the relevant studies have concerned alen-
dronate because this is the most widely used BP. The effect 
is probably common to all BPs, but, at the moment, there 
are no findings available for the other agents. Nevertheless, 
femoral shaft fractures are rare in BP users, indicating that 
the pathogenesis is complex and probably not directly related 
to BP treatment, and probably more related to patient charac-
teristics. A genetic susceptibility of osteoclasts to BP-induced 
oversuppression has been postulated,78 as well as the presence 
of one or more predisposing factors, such as diabetes mellitus, 
chronic corticosteroid treatment for pulmonary diseases, rheu-
matoid arthritis, and severe osteoarthritis,79 or the existence 
of femur cortical hypertrophy, that is often present before the 
beginning of treatment.79 The question of whether low-energy 
subtrochanteric or proximal femoral shaft fractures are more 
frequent in alendronate (or any other BP) users compared 
with nonusers cannot be answered at present.
Patients treated with the more widely used BPs should be 
informed that persistent and increasing pain in the region of 
the upper part of the femur may be prodromal of a proximal 
diaphysis fracture, and a radiologic evaluation should be 
performed.
Osteonecrosis of the jaw
Osteonecrosis of the jaw (ONJ) developing during BP treat-
ment is a form of chronic osteomyelitis, involving mainly the 
jaw and maxilla, and attributable to pathogens usually present 
in the mucosa of the mouth, such as Actinomyces israeli.80 
In addition to BP use, other risk factors have been identi-
fied, including coexisting solid tumors or multiple myeloma Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
128
Dalle Carbonare et al
treated by chemotherapy, and other conditions associated with 
  immunosuppression, such as diabetes mellitus and corticos-
teroid treatment. A dental procedure is often the precipitating 
factor, especially if associated with bad dental hygiene and 
inadequate antibiotic propylaxis.80 The incidence is very low, 
ie, less than 1/100,000 in PO patients treated with BPs in 
  Germany81 and 0.01%–0.04% in Australia.82 In the   HORIZON 
study, no cases of ONJ were observed in 7000 patients, and 
a retrospective analysis showed two cases of ONJ, one in the 
treated group and one in the placebo group.83
Many authors have suggested that the pathogenesis of 
ONJ is directly linked to osteonecrosis of bone due to exces-
sive suppression of bone turnover.47 In contrast, histologic 
analyses showed that ONJ is a typical osteomyelitis charac-
terized by a high cellular infiltrate, and an intense osteoclast 
and osteoblast reaction indicating that bone turnover is not 
oversuppressed by the therapy.48 Oversuppression of bone 
turnover after bisphosphonates has been discounted by 
bone biopsy analyses in osteoporotic patients treated with 
zoledronic acid.84
The cumulative BP dose has been proposed as one of the 
most important risk factors for the development of ONJ,85 
but the wide range of doses found to have been administered 
at the onset of ONJ suggests that this is unlikely. Recently, 
it has been proposed that soft tissue toxicity from BPs might 
be involved in the pathogenesis of ONJ.86 Moreover, the 
majority of cases of ONJ reported up until now have been 
described in patients taking BPs for bone metastases, in which 
higher doses are used.
Consequently, it can be concluded that, nowadays, the 
role of BPs in the development of ONJ is still uncertain and 
a matter of debate, given that BPs are probably only one of 
many treatment-related factors. At the moment, there are 
some guidelines and general recommendations to prevent 
ONJ, but are not widely accepted.87,88 It seems useful to 
maintain adequate oral hygiene and use antibiotic prophy-
laxis in the event of a dental procedure, but suspension of 
BP treatment would seem unhelpful, given the long duration 
of drug persistence in bone.
Efficacy
Alendronate, risedronate, ibandronate, and zoledronate 
are approved for the treatment of osteoporosis (Table 1). 
All these molecules demonstrate a significant reduction of 
fracture risk (Figure 3).
Alendronate is available in both daily (10 mg) and 
weekly (70 mg) formulations. It has been shown to increase 
BMD significantly at all skeletal sites, and after 3 years 
the   increment at the lumbar spine was about 8%, while 
the   reduction of fracture risk was 47% for vertebral and 
40%–50% for nonvertebral fractures.89 Prolonged treatment 
(data available for up to 10 years) has demonstrated the per-
sistent efficacy of alendronate, characterized by a continuous 
increase in BMD and a reduction of new vertebral fractures.1 
Discontinuation of alendronate is characterized by a long 
inhibition of bone turnover that guarantees the persistence of 
pharmacologic effects of the drug that are strictly dependent 
on the duration of treatment.
Recently, a new weekly formulation of alendronate 
supplemented with two different dosages of cholecalciferol 
(2800 IU and 5600 IU) has been approved. The once-weekly 
alendronate-vitamin D tablet was shown to increase patient 
compliance, to provide an antiresorptive efficacy equivalent 
to once-weekly alendronate 70 mg without cholecalciferol, 
and to improve vitamin D status. It was not associated with 
hypercalcemia, hypercalciuria, or other adverse effects.90,91
Risedronate is marketed in three formulations, ie, 5 mg 
daily, 35 mg weekly, and 150 mg monthly (75 mg on 2 
consecutive days in Europe).92 Like alendronate, risedronate 
significantly increases BMD by approximately 6% at the 
lumbar spine after 3 years of treatment (Table 1). Fracture 
risk reduction was significant at both the vertebral (−49%) 
and femoral sites (−40%).93
Risedronate is characterized by a rapid onset of anti-
fracture effect that becomes significant within 6 months of 
starting treatment. Prolonged treatment (7-year data avail-
able) demonstrated the persistence of a risedronate effect 
on BMD increase and fracture prevention.43 However, after 
discontinuation, bone turnover comes back rapidly towards 
the pretreatment level, although fracture risk reduction is 
maintained for more than 1 year.44
Risedronate and alendronate are usually prescribed 
for the treatment of PO, but they are also approved for 
glucocorticoid-induced osteoporosis (GIO) and for male 
osteoporosis.94–97
Ibandronate is available in both oral (150 mg monthly) 
and intravenous (3 mg every 3 months) formulation. It has 
been registered for osteoporosis on the basis of studies 
using a daily dosage of 2.5 mg which showed a significant 
vertebral fracture risk reduction (62% with the daily and 
50% with the intermittent formulation after 3 years versus 
placebo), while the reduction of nonvertebral fractures was 
evident only in a post hoc analysis in a higher-risk subgroup 
of patients (femoral T score , −3).42,98,99 Nevertheless, it is 
now marketed at an oral dosage of 150 mg monthly or 3 mg 
intravenously every 3 months.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Zoledronic acid
The first dose-finding trial was of 1 year’s duration, and 
included 351 postmenopausal women with a lumbar spine 
BMD T score # −2.0.9 Patients were randomized to receive 
placebo or intravenous zoledronic acid at doses of 0.25 mg, 
0.5 mg, or 1 mg every 3 months, 2 mg every 6 months, or a 
single dose of 4 mg.
All patients treated with zoledronic acid showed a 
significant increase in lumbar BMD (mean values 4.3%–5.1% 
higher than for placebo) and in femoral neck BMD (mean 
values 3.1%–3.5% higher than for placebo) at the end of the 
1-year study. Markers of bone resorption and formation were 
also significantly decreased in comparison with placebo at 
all time points (months 3, 6, and 12). To assess bone quality, 
a subset of patients underwent transiliac bone biopsy after 
tetracycline double-labeling and these analyses showed 
normal bone structure in patients treated with zoledronate, 
with no evidence of histologic alterations, osteomalacia, or 
signs of bone turnover below the limit of the premenopausal 
range.9
To generate more data on long-term treatment, all patients 
were allowed to extend their treatment for additional 2 years.100 
Lumbar spine BMD increased at 5 years from a mean of 6.4% 
to 9.0% and from 4.9% to 5.5% at the proximal femur. Levels 
of the resorption serum marker, Type I collagen C-telopeptide 
(β-CTx), were consistently reduced to around the standard 
premenopausal range during the observation period. Bone 
resorption markers remained within the premenopausal refer-
ence range during long-term treatment, but there was a clear 
trend of increasing values after the evaluation period. After 
5 years of treatment, b-ALP decreased by a mean of 36.6%, 
while in the 1-year core study b-ALP reduction reached its 
nadir at 6 months, with an upward trend in the second half 
of the study period. At the end of the core study, about 37% 
of patients did not reach a 30% reduction in b-ALP levels,100 
which is considered the cutoff for achieving a clinical benefit 
with regard to nonvertebral fractures.101
On the basis of these results, the HORIZON study was 
planned. This 3-year, international, randomized, double-
blind, placebo-controlled trial was designed to demonstrate 
the efficacy of zoledronic acid 5 mg once yearly in reducing 
fractures at all prevalent bone sites.8 The patients enrolled 
were osteoporotic women aged between 65 and 89 years 
with a BMD T score #−2.5 at the femoral neck or a T score 
of #−1.5, and with radiologic evidence of at least two mild 
vertebral fractures or one moderate vertebral fracture. The 
patients were randomly assigned to receive either one infu-
sion of zoledronic acid or placebo once a year for 3 years. 
All subjects also received daily oral calcium (1000–1500 mg) 
and vitamin D (400–1200 IU) supplementation.
At 36 months, zoledronic acid significantly reduced the 
risk of new morphometric vertebral fractures by 70%, hip 
fractures by 41%, and nonvertebral fractures by 25%.6 A sig-
nificant increase of BMD at all skeletal sites was consistently 
observed, in particular, +6.02% at the total hip, +5.06% at the 
femoral neck, and +6.71% at the lumbar spine. Markers of 
bone formation (b-ALP and N-terminal propeptide of Type I 
collagen), and resorption (β-CTx) showed a rapid and stable 
trend toward the standard premenopausal reference range.8
The HORIZON investigators also evaluated zoledronic 
acid as a secondary prevention strategy for osteoporotic 
fractures. They randomized 2127 subjects within 90 days 
of hip fracture surgery to receive intravenous zoledronic 
acid 5 mg or placebo on a yearly basis. At 36 months, the 
treated group showed significantly increased BMD at the 
total hip and femoral neck compared with the placebo group. 
Over a 1.9-year median follow-up, the investigators observed 
a significant decrease in any new fracture (absolute risk 
reduction [ARR] 5.3%), clinical vertebral fractures (ARR 
2.1%), nonvertebral fractures (ARR 3.1%), and recurrent 
Table 1 Bisphosphonates approved for the treatment of osteoporosis
Bisphosphonate Dosage Administration Indications  Lumbar spine 
BMD increase 
Alendronate 10 mg (daily) 
70 mg (weekly)
Oral Postmenopausal 
glucocorticoid 
male
+8%64 
+2.9%94 
+5.3%96
Risedronate 5 mg (daily) 
35 mg (weekly) 
150 mg (monthly)
Oral Postmenopausal 
glucocorticoid 
male 
+6%93 
+2.7%95 
+4.6%97
ibandronate 150 mg (monthly) 
3 mg (quarterly)
Oral 
intravenous
Postmenopausal  +5%98 
+6.5%99
Zoledronate 5 mg (yearly) intravenous Postmenopausal 
male
+6.7%8 
+6.3%102 Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
130
Dalle Carbonare et al
hip fractures (ARR 1.5%). In this population at high risk for 
recurrent and potentially fatal fractures, the zoledronic acid-
treated group also experienced a survival advantage (relative 
risk reduction [RRR] 28%, ARR 3.7%).102 This was the first 
study highlighting a reduction in mortality after treatment 
with bisphosphonates.
Within the efficacy data for the bisphosphonates, 
some evidence has emerged supporting the possibility of 
switching between different formulations. For example, in 
a one-year, randomized, active-controlled trial, the safety 
of   switching from alendronate to zoledronic acid was evalu-
ated in postmenopausal women with low BMD.103 Patients 
enrolled in this study had lumbar spine or femoral neck BMD 
T scores # −2.0. All patients were treated with alendronate 
for at least one year (average 4 years). Subjects were random-
ized to either a 15-minute intravenous infusion of zoledronic 
acid 5 mg plus 52 weeks of oral placebo or to an infusion of 
placebo plus 52 weeks of weekly oral alendronate 70 mg. 
Fx%
A
B
40
30
20
10
0
−47% −49% −62% −71%
40
30
20
10
0
−20% −39% ns −37%
Controls Treated
Alendronate Risedronate Ibandronate Zoledronate
Figure 3 Reduction of new vertebral A) and femoral B) fractures after treatment with several common bisphosphonates.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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The lumbar spine BMD increase compared with baseline 
was similar for the two groups. Bone resorption markers 
measured were Type I collagen N-telopeptide corrected for 
creatinine and serum β-CTx, while the bone formation mark-
ers measured were serum b-ALP and N-terminal propeptide 
of Type I collagen). In the alendronate group, the urinary 
and serum biomarkers of bone resorption remained close to 
baseline values. In contrast, biomarkers were significantly 
reduced in the zoledronate-treated group after 3 months 
(P , 0.05), returned to baseline after 6 months, and signifi-
cantly increased compared with baseline (P , 0.05) at the 
end of the study, but were still within the premenopausal 
reference range.
No signs of abnormalities in bone structure were revealed 
in biopsies obtained in a subgroup of patients. The safety 
profile was similar between the treatments, with the excep-
tion of the expected higher incidence of acute phase flu-like 
syndrome in the group treated wth zoledronic acid (36.3% 
versus 21.4%).
Zoledronic acid and glucocorticoid-
induced osteoporosis
As mentioned earlier, alendronate and risedronate are 
approved for GIO. More recently, zoledronate has also been 
registered for this indication. The efficacy and safety of once-
yearly intravenous zoledronic acid 5 mg in GIO has been 
evaluated in a one-year randomized, multicenter, double-
blind, stratified study using daily oral risedronate as the active 
control. This study was conducted in 833 men and women 
aged 18–85 years. The study prerequisite was treatment 
with .7.5 mg/day or equivalent of oral prednisone.104
Patients were stratified according to the duration of glu-
cocorticoid treatment prior to their inclusion in the study, 
ie, less than 3 months (prevention arm) or more than three 
months (treatment arm). Adequate calcium supplementa-
tion of 1000 mg/day was given to all patients, as well as 
cholecalciferol 400–1000 IU/day. After 1 year of treatment, 
zoledronate-treated patients showed a significantly greater 
increase of lumbar spine BMD compared with those on oral 
risedronate (4.06% versus 2.71%, respectively, P = 0.0001) 
and of femoral neck BMD (1.45% versus 0.39, respectively, 
P = 0.005). Similar results were observed in the prevention 
group. Zoledronic acid showed a faster and more persistent 
inhibitory effect on bone resorption markers than risedronate 
(Figure 4). In contrast, the inhibition of bone formation mark-
ers was higher in the risedronate-treated group. This effect 
could represent an advantage in this particular setting, in 
which the reduction of BMD with an associated increased 
risk of fracture occurs within a few months after starting 
glucocorticoid treatment.105
Zoledronic acid and male osteoporosis
Twenty percent of men older than 60 years will experience 
a fracture, but age-related bone loss in men is still under-
recognized and undertreated.106 Hip fractures increase the 
mortality risk by 4-fold in the first 3 months after a fracture, 
and 1-year mortality reaches 20%.107 Alendronate and rise-
dronate are approved for the treatment of osteoporosis in men. 
These BPs have been shown to induce a significant increase 
of lumbar spine and femoral BMD, as well as a reduction in 
vertebral fractures, but there are still limited data available 
for nonvertebral fractures.96,97
The HORIZON investigators evaluated zoledronic acid 
in the secondary prevention of osteoporotic fractures and, 
of the 2127 subjects recruited, 24% were men.102 Within 90 
days of surgical repair of a hip fracture, participants received   
5 mg of intravenous zoledronic acid or placebo. At 36 months, 
they had significantly increased BMD at the total hip and 
  femoral neck compared with the placebo group and a sig-
nificant decrease in any new fracture. As already mentioned, 
the treated population had a survival advantage (RRR 28%, 
ARR 3.7%) that was greater in men than in women (overall 
mortality ARR 6.4%) and, interestingly, a marked   reduction 
in cardiac-related deaths (RRR 62.0% and RRR 4.8%, 
respectively).102 These data are interesting, although further 
confirmations are needed.
Zoledronic acid and hormone 
suppressive therapy
Aromatase inhibitors and osteoporosis
Aromatase inhibitors result in a longer disease-free survival 
interval and produce fewer endometrial and thromboembo-
lic adverse events (AEs) than tamoxifen.108 Consequently, 
more women are receiving aromatase inhibitors as first-line 
adjuvant hormonal therapy or following tamoxifen therapy. 
However, aromatase inhibitors inhibit almost completely the 
production of endogenous estrogens that are necessary for 
bone health,109 and women treated with these agents have a 
rapid reduction of BMD associated with a rapid increase of 
bone turnover and a high risk of fractures.110 Zoledronic acid 
has been studied for the prevention and treatment of bone loss 
and for the reduction of risk fracture in this population.
The two most important studies performed, Z-FAST and 
Zo-FAST, showed that early-stage breast cancer patients who 
received zoledronic acid (4 mg intravenously every 6 months) 
had better preserved bone mass during the first 12 months of Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
132
Dalle Carbonare et al
aromatase inhibitor therapy compared with patients allocated 
to delayed administration of zoledronic acid (P , 0.001 at 
both BMD sites in both studies).110–112 The positive effect 
of zoledronic acid on BMD is consistent with the rapid and 
sustained decrease of serum collagen Type 1 N-telopeptide 
and b-ALP during the first 12 months of adjuvant letrozole 
therapy. In light of these findings, clinicians prescribing aro-
matase inhibitors should consider a fracture risk assessment 
and effective treatment to prevent bone loss and fractures.
Androgen inhibitors and osteoporosis
Prostate cancer is a common disease in men, and andro-
gen deprivation therapy (ADT) is associated with a risk 
of osteoporosis and fractures. Zoledronic acid has been 
tested successfully in this setting.113 Two studies evaluated 
zoledronate 4 mg intravenously every 3 months in men with 
nonmetastatic prostate cancer and embarking on ADT. At 1 
year, BMD at the lumbar spine, femoral neck, and total hip 
decreased 2%–3% in the placebo group, while the treated 
group showed significant increases at the same skeletal sites 
(6.7%–7.8% at the lumbar spine, 3.3%–3.6% at the femoral 
neck, and 3.8%–3.9% at the total hip).113–115
Other applications
Hiv-related bone loss
Human immunodeficiency virus (HIV) infection and highly-
active antiretroviral therapy are associated with low BMD 
and osteoporosis. Brown et al found that the prevalence of 
osteoporosis in HIV-infected individuals is more than three 
times greater compared with HIV-noninfected controls.116 An 
annual infusion of 4 mg of zoledronate in HIV-infected . men 
with decreased BMD receiving antiretroviral therapy achieved 
a significant decrease in bone turnover markers (urinary col-
lagen Type 1 N-telopeptide −61% and serum total ALP –21%) 
by 3 months and a significant increase of lumbar spine (4.6%) 
and total hip (6.3%) compared with the control group.117
Transplant-related bone disease
Osteoporosis is an increasingly frequent complication of 
  end-stage organ failure, and bone loss and fracture risk is 
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particularly high both before and after organ   transplantation. 
Research has demonstrated the efficacy of oral bisphos-
phonates118,119 as well as of an intravenous formulation of 
zoledronic acid120 in transplant patients. In particular, a study 
by Crawford et al in liver transplantation demonstrated that 
zoledronic acid had a positive effect on bone density that was 
independent of the glucocorticoid dose being administered. 
Bone loss was significant at the femoral level, while bone 
density was maintained in the group treated with zoledronic 
acid, in whom a higher degree of bone turnover suppression 
was also observed.120
Previous studies on osteoporosis therapies in transplanted 
recipients showed inconsistent and unconvincing findings, 
but the data for zoledronate suggest that a more potent bis-
phosphonate administered as soon as is feasible after surgery 
and at more frequent intervals can prevent bone loss after 
transplantation. The use of zoledronate in this population 
appeared to be safe, in particular there was no reported 
impairment of renal function.120
Prevention of postmenopausal 
osteoporosis
Zoledronic acid has been recently investigated for the pre-
vention of PO in a 2-year, randomized, multicenter, double-
blind, controlled trial study of 1140 osteopenic women who 
were assigned to receive two infusions of zoledronic acid 
5 mg (one per year), only one infusion of 5 mg, or placebo.46
After 2 years, spine BMD was increased by 5.18% 
in women who received the twice-yearly zoledronic acid 
infusion and by 4.18% in those who received a once-yearly 
zoledronic acid infusion, compared with a –1.32% decrease 
in the placebo group. A significant BMD increase was also 
observed at the proximal femur. In particular, total hip 
BMD increased by 2.91% with the twice-yearly zoledronic 
acid infusion, by 2.28% with the once-yearly zoledronic acid 
infusion, compared with –1.45% in the placebo group.
The reduction in bone turnover markers showed a similar 
pattern from baseline to 12 months. At month 12, bone turn-
over decreased significantly in the twice-yearly zoledronic 
acid infusion group after the second infusion, but slightly 
increased during the second year in the once-yearly zole-
dronic acid infusion group.
The results of this study suggest that zoledronic acid 
could also be effective for the prevention of bone loss in 
osteopenic postmenopausal women. Although information on 
fractures is not yet available, these data are of interest because 
they suggest that the use of zoledronic acid is beneficial in 
patients with a moderate fracture risk or with pathologic 
conditions associated with bone loss in which BPs have not 
been yet extensively studied (eg, in transient immobiliza-
tion, anorexia, early menopause, and conditions associated 
with high bone turnover, including hyperparathyroidism and 
hyperthyroidism).
Patient considerations
Patients are strictly monitored and compliance and persis-
tence are generally high in controlled clinical trials, but it is 
difficult to monitor compliance in everyday clinical practice 
because compliance data are usually collected from patient 
self-reporting, which may be inaccurate. It has been reported 
that compliance for patients treated with oral bisphospho-
nates is poor after 12 months, and compliance rates decrease 
steadily over time.49,50,121
There is good evidence demonstrating that compliance 
over one year is better with weekly administration than with 
daily dosing,122 and even better persistence is achieved with 
the monthly formulations of ibandronate.123
Poor compliance with oral formulations can explain 
the difference between rates of BMD increase and fracture 
incidence seen in clinical trials and in daily clinical prac-
tice.49,50,121 There are many reasons explaining low persistence 
and poor compliance, ie, lack of immediate benefits that can 
be recognized by patients, real or perceived adverse effects, 
costs, and an inconvenient oral dosing regimen, the latter 
being the major cause for noncompliance, as previously 
discussed. Adherence with alendronate is significantly bet-
ter with the weekly oral formulation than with the daily one. 
From another point of view, once-weekly or monthly dosing 
may be harder to remember than daily dosing.121
The possibility of once-yearly intravenous BP administra-
tion provides the opportunity to increase patient compliance, 
which will optimize clinical, densitometric, and antifracture 
outcomes. In the case of once-yearly zoledronic acid, com-
pliance is 100% during the first year of follow-up not only 
in trials but also in clinical practice. As a consequence, the 
reduction of fracture rate in real life would be expected to be 
similar to that observed in the clinical trials.8,121
At present, there are still no studies focused on patient 
satisfaction and preference, although some data can be 
extrapolated from the larger clinical trials. In general, as 
expected, yearly intravenous BP administration was preferred 
over weekly oral administration,45,103 despite some authors 
reporting 20% of patients having a preference for weekly oral 
therapy, and 14% having no preference for either option.124 
The data available indicate that intravenous BP administra-
tion is generally well tolerated and preferred instead to oral Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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formulations, the latter often being more commonly used in 
daily clinical practice, because of their ready availability for 
general practitioners.
Conclusion
BPs have modified the prognosis for patients with osteo-
porosis. They reduce the incidence of fragility fractures 
significantly, and improve quality of life for patients with 
bone disease. The different molecules and formulations avail-
able allow modulation of treatment in the individual patient, 
increasing compliance and adherence, and thus optimizing 
the clinical outcome. The recent introduction of yearly 
administration of intravenous zoledronic acid represents a 
powerful option in the management of patients, and is able 
to achieve compliance, adherence, and efficacy rates similar 
to those observed in clinical studies.
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